For NHS & Health Plans

Catch hormonal transitions upstream.

80% of women experience hormonal transition symptoms. 75% never receive treatment. The result: misattributed A&E visits, unnecessary referrals, and avoidable downstream costs. MARKABLE surfaces wellness patterns that may indicate emerging needs, before they escalate. Aligned with NICE guidelines for menopause care.

Download Health Plan Brief Request Custom Savings Model

A significant gap in women's health provision

80%

Experience symptoms¹

75%

Never receive treatment²

50-65%

Discontinue hormone therapy in year one³

Objective monitoring tools exist

Health Equity

An access challenge that remains largely unaddressed.

Monitoring hormonal transitions today requires a GP visit, a blood draw, an NHS referral, transportation, and time off work. MARKABLE requires a smartphone and 10 minutes.

"The women who need help most are the ones least likely to have access to it. Smartphone-based monitoring removes every barrier except awareness."

GP visit requiredReduced

NHS referral pathwayReduced

Transportation to clinicReduced

Time off workReduced

Repeat monitoring costReduced

Specialist availabilityReduced

The Platform

Three data channels. One wellness signal.

MARKABLE fuses facial biomarker analysis, cognitive performance testing, and structured symptom capture into a single longitudinal wellness profile per member.

Facial Biomarkers

AI analysis of dermal, periorbital, and volumetric patterns associated with hormonal change. Smartphone camera, ~2 min.

Cognitive Battery

Micro-tasks measuring attention, memory, and processing speed. Calibrated to functions sensitive to hormonal fluctuations. ~5 min.

Symptom Capture

70+ symptom domains with algorithm-driven pattern detection. Surfaces correlations that self-report alone cannot reveal. ~3 min.

~10 min
per member check

200-500
typical pilot cohort

3-6 mo
pilot duration

Research & Validation

Developed and tested with real data.

264

Participants in research dataset

Independent data channels

70+

Symptom domains mapped

Positioned as a general wellness product in accordance with MHRA and UK regulatory guidelines. Not a medical device. Research methodology documentation available under NDA.

Questions from NHS and health plan leaders

What's the business model? +

We offer flexible models including per member per month, per-use, and pilot-based pricing. Contact us for a custom proposal based on your member population and use case.

How does this integrate with our systems? +

For initial pilots, no integration is needed. Members access MARKABLE via a web link. For scaled deployments, we offer API access and can discuss FHIR/HL7 integration pathways with your technical team.

What clinical evidence exists? +

Our platform was developed and tested on a 264-participant research dataset across three hormonal status groups. We can share our research summary and methodology documentation under NDA. Prospective validation studies are in planning.

Who owns the member data? +

The member owns their data. NHS trusts and health plans receive only aggregate, de-identified population insights. Individual-level data is never shared without explicit member consent.

Is this MHRA-cleared? +

MARKABLE is positioned as a general wellness product for personal awareness and monitoring. It does not require MHRA clearance under current guidelines for general wellness products. It does not diagnose, treat, cure, or prevent any disease.

How does this align with NICE guidelines? +

NICE guidelines (NG23) recommend that menopause diagnosis should be based on symptoms and clinical assessment. MARKABLE supports this by providing structured, longitudinal symptom data and wellness trends to GPs, enhancing the quality of clinical conversations without replacing clinical judgement.

Can we run a pilot? +

Yes. We offer structured pilot programmes with defined cohorts, success metrics, and timeline. Typical pilot: 200-500 members, 3-6 months, with a dedicated success manager.